---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-23-000113"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2023-09-22T23:59:59+00:00"
generated_at: "2026-06-10T09:30:16.354953+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# MacroGenics amends TZIELD royalty deal; retains $50M sales milestone and 50% royalty share

## Summary
- Terminated Royalty Purchase Agreement with DRI; Aventis (Sanofi sub) now receives royalty directly from Provention Bio.
- Asset Purchase Agreement amended to include $50M milestone payment from Sanofi if TZIELD net sales hit certain level.
- MacroGenics retains 50% royalty on global TZIELD sales above an annual threshold.
- Sanofi guarantees the $50M sales milestone obligation to MacroGenics.
- All prior obligations under the Royalty Purchase Agreement eliminated as of September 19, 2023.

## SEC filing metadata
- accession: 0001125345-23-000113
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2023-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000113/0001125345-23-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000113/mgnx-20230919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-23-000113
- JSON: https://secwatch.observer/filing/0001125345-23-000113.json
- Plain text: https://secwatch.observer/filing/0001125345-23-000113.txt

## Key facts
- Material Agreements
  MACROGENICS INC amended Asset Purchase Agreement with Provention Bio, Inc. valued at Amendment to incorporate Sales Milestone Payment obligation and guaranty by Sanofi, and eliminate Pr (effective 2023-09-19).
  - Action: amendment
  - Agreement: asset purchase
  - Counterparty: Provention Bio, Inc.
  - Value: Amendment to incorporate Sales Milestone Payment obligation and guaranty by Sanofi, and eliminate Pr
  - Effective: 2023-09-19
  source text: On September 19, 2023, the Company and Provention Bio entered into an amendment of the Asset Purchase Agreement (the “Asset Purchase Agreement Amendment”) to incorporate the Sales Milestone Payment obligation from the Royalty Purchase Agreement, along with a guaranty of such obligation by Sanofi and to eliminate any obligation for Provention Bio to pay the Royalty Interest to the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000113/0001125345-23-000113-index.htm
- Material Agreements
  MACROGENICS INC terminated Royalty Purchase Agreement with DRI Healthcare Acquisitions LP valued at Mutual Termination Agreement terminated the Royalty Purchase Agreement (effective 2023-09-19).
  - Action: termination
  - Counterparty: DRI Healthcare Acquisitions LP
  - Value: Mutual Termination Agreement terminated the Royalty Purchase Agreement
  - Effective: 2023-09-19
  source text: On September 19, 2023, the Company and Aventis concurrently entered into a Mutual Termination Agreement terminating the Royalty Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000113/0001125345-23-000113-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.